According to Adam Steensberg, CEO of the Danish biotechnology company Zealand Pharma, as competitors novo-nordisk and eli lilly dominate the weight loss drug market, the company's goal is to target the "next generation" of weight loss drugs. Zealand has announced the early clinical trial results of their own GLP-1 therapy, but the standalone weight loss candidate drug sets Zealand apart from other pharmaceutical companies. Zealand is looking for a pharmaceutical partner to enter the global market.
减肥药生产商Zealand Pharma：公司瞄准“下一代”减肥药
Weight loss drug manufacturer Zealand Pharma: the company is targeting the "next generation" of weight loss drugs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated